Principal Investigators

    XU, XIN


    National Center for Advancing Translational Sciences

    Contact information of lead PI



    Title of project or programme

    Pre-Clinical Development of EDN-OL1 for Alzheimers Disease

    Source of funding information

    NIH (NIA)

    Total sum awarded (Euro)


    Start date of award

    Total duration of award in years



    Acquired Cognitive Impairment... Aging... Alzheimer's Disease... Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)... Brain Disorders... Dementia... Neurodegenerative... Neurosciences... Translational Research

    Research Abstract

    More than 5 million Americans now have Alzheimers disease (AD), the sixth leading cause of death in the United States, and no disease-modifying drug is available. EDN-OL1, a patented antisense phosphorothioate oligonucleotide, crosses the blood-brain barrier after intravenous dosing and reduces production of amyloid precursor protein (APP) and, consequently, amyloid proteins in the brains of mouse models of AD. The clinical benefit to AD patients may best be anticipated as a decrease in the rate of cognitive decline. Edunn requested program assistance to carry out specific tasks for pre-clinical development of EDN-OL1 to support submission of an Investigational New Drug (IND) application to enable clinical trials for the Alzheimers indication, ultimately leading to FDA approval for treatment of AD patients. The lab has made progress towards the completion of the following studies: – Synthesis of Good Manufacturing Practice (GMP) and non-GMP material – Formulation development

    Further information available at:

Types: Investments < €500k
Member States: United States of America
Diseases: N/A
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF